Research ExplorerPublicationsPrognostic factors for survival of patients with newly diagn...

Prognostic factors for survival of patients with newly diagnosed chronic GVHD according to NIH criteria

Standard

Prognostic factors for survival of patients with newly diagnosed chronic GVHD according to NIH criteria. / Ayuketang, Francis Ayuk; Veit, Ronja; Zabelina, Tatiana; Bussmann, Lara; Christopeit, Maximilian; Alchalby, Haefaa; Wolschke, Christine; Lellek, Heinrich; Bacher, Ulrike; Zander, Axel R; Kröger, Nicolaus.

In: ANN HEMATOL, Vol. 94, No. 10, 10.2015, p. 1727-32.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Ayuketang, FA, Veit, R, Zabelina, T, Bussmann, L, Christopeit, M, Alchalby, H, Wolschke, C, Lellek, H, Bacher, U, Zander, AR & Kröger, N 2015, 'Prognostic factors for survival of patients with newly diagnosed chronic GVHD according to NIH criteria', ANN HEMATOL, vol. 94, no. 10, pp. 1727-32. https://doi.org/10.1007/s00277-015-2452-6

APA

Ayuketang, F. A., Veit, R., Zabelina, T., Bussmann, L., Christopeit, M., Alchalby, H., Wolschke, C., Lellek, H., Bacher, U., Zander, A. R., & Kröger, N. (2015). Prognostic factors for survival of patients with newly diagnosed chronic GVHD according to NIH criteria. ANN HEMATOL, 94(10), 1727-32. https://doi.org/10.1007/s00277-015-2452-6

Vancouver

Ayuketang FA, Veit R, Zabelina T, Bussmann L, Christopeit M, Alchalby H et al. Prognostic factors for survival of patients with newly diagnosed chronic GVHD according to NIH criteria. ANN HEMATOL. 2015 Oct;94(10):1727-32. https://doi.org/10.1007/s00277-015-2452-6

Bibtex

@article{a7bcb8df7cc24027971276383dadc67f,
title = "Prognostic factors for survival of patients with newly diagnosed chronic GVHD according to NIH criteria",
abstract = "Chronic graft versus host disease (cGvHD) is the most common cause of late morbidity and mortality after allogeneic hematopoietic stem cell transplantation (HSCT). We retrospectively evaluated the impact of NIH classification on outcome of patients at our center. Primary endpoint was overall survival at 5 years. Two hundred one patients with cGVHD according to NIH were included. Platelets <100,000/μl on day of diagnosis of cGvHD (HR 2.97, 95 % CI 1.7-5.3, p < 0.001), female donor (HR 1.78, 95 % CI 1.0-3.2, p = 0.05), and reduced intensity conditioning (HR 1.95, 95 % CI 1.0-3.8, p = 0.05) impacted overall survival. Non-relapse mortality (NRM) was higher for patients with low vs. high platelets: 26 % (95 % CI 14-40) vs. 6 % (95 % CI 2-10), p < 0.001, and tended to be higher for female vs. male donor: 14 % (95 % CI 7-23) vs. 7 % (95 % CI 3-13), p = 0.08. Relapse tended to be higher for recipients of reduced intensity conditioning (RIC) vs. myeloablative conditioning (MAC): 33 % (95 % CI 23-43) vs. 20 % (95 % CI 10-31), p = 0.06. After excluding patients with myeloma and lymphoma, IgG serum levels at diagnosis of cGvHD of 122 patients were correlated with survival. IgG levels above normal were associated with worse 2-year overall survival (OS), p = 0.04, compared to normal or low IgG levels. Platelet count at diagnosis remains the most valid prognostic factor for survival of patients with cGvHD even in the era of NIH grading. High IgG level at diagnosis of cGVHD represents a potential negative prognostic parameter that deserves further investigation.",
keywords = "Adolescent, Adult, Aged, Female, Graft vs Host Disease, Humans, Male, Middle Aged, National Institutes of Health (U.S.), Prognosis, Retrospective Studies, Survival Rate, United States, Young Adult",
author = "Ayuketang, {Francis Ayuk} and Ronja Veit and Tatiana Zabelina and Lara Bussmann and Maximilian Christopeit and Haefaa Alchalby and Christine Wolschke and Heinrich Lellek and Ulrike Bacher and Zander, {Axel R} and Nicolaus Kr{\"o}ger",
year = "2015",
month = oct,
doi = "10.1007/s00277-015-2452-6",
language = "English",
volume = "94",
pages = "1727--32",
journal = "ANN HEMATOL",
issn = "0939-5555",
publisher = "Springer",
number = "10",

}

RIS

TY - JOUR

T1 - Prognostic factors for survival of patients with newly diagnosed chronic GVHD according to NIH criteria

AU - Ayuketang, Francis Ayuk

AU - Veit, Ronja

AU - Zabelina, Tatiana

AU - Bussmann, Lara

AU - Christopeit, Maximilian

AU - Alchalby, Haefaa

AU - Wolschke, Christine

AU - Lellek, Heinrich

AU - Bacher, Ulrike

AU - Zander, Axel R

AU - Kröger, Nicolaus

PY - 2015/10

Y1 - 2015/10

N2 - Chronic graft versus host disease (cGvHD) is the most common cause of late morbidity and mortality after allogeneic hematopoietic stem cell transplantation (HSCT). We retrospectively evaluated the impact of NIH classification on outcome of patients at our center. Primary endpoint was overall survival at 5 years. Two hundred one patients with cGVHD according to NIH were included. Platelets <100,000/μl on day of diagnosis of cGvHD (HR 2.97, 95 % CI 1.7-5.3, p < 0.001), female donor (HR 1.78, 95 % CI 1.0-3.2, p = 0.05), and reduced intensity conditioning (HR 1.95, 95 % CI 1.0-3.8, p = 0.05) impacted overall survival. Non-relapse mortality (NRM) was higher for patients with low vs. high platelets: 26 % (95 % CI 14-40) vs. 6 % (95 % CI 2-10), p < 0.001, and tended to be higher for female vs. male donor: 14 % (95 % CI 7-23) vs. 7 % (95 % CI 3-13), p = 0.08. Relapse tended to be higher for recipients of reduced intensity conditioning (RIC) vs. myeloablative conditioning (MAC): 33 % (95 % CI 23-43) vs. 20 % (95 % CI 10-31), p = 0.06. After excluding patients with myeloma and lymphoma, IgG serum levels at diagnosis of cGvHD of 122 patients were correlated with survival. IgG levels above normal were associated with worse 2-year overall survival (OS), p = 0.04, compared to normal or low IgG levels. Platelet count at diagnosis remains the most valid prognostic factor for survival of patients with cGvHD even in the era of NIH grading. High IgG level at diagnosis of cGVHD represents a potential negative prognostic parameter that deserves further investigation.

AB - Chronic graft versus host disease (cGvHD) is the most common cause of late morbidity and mortality after allogeneic hematopoietic stem cell transplantation (HSCT). We retrospectively evaluated the impact of NIH classification on outcome of patients at our center. Primary endpoint was overall survival at 5 years. Two hundred one patients with cGVHD according to NIH were included. Platelets <100,000/μl on day of diagnosis of cGvHD (HR 2.97, 95 % CI 1.7-5.3, p < 0.001), female donor (HR 1.78, 95 % CI 1.0-3.2, p = 0.05), and reduced intensity conditioning (HR 1.95, 95 % CI 1.0-3.8, p = 0.05) impacted overall survival. Non-relapse mortality (NRM) was higher for patients with low vs. high platelets: 26 % (95 % CI 14-40) vs. 6 % (95 % CI 2-10), p < 0.001, and tended to be higher for female vs. male donor: 14 % (95 % CI 7-23) vs. 7 % (95 % CI 3-13), p = 0.08. Relapse tended to be higher for recipients of reduced intensity conditioning (RIC) vs. myeloablative conditioning (MAC): 33 % (95 % CI 23-43) vs. 20 % (95 % CI 10-31), p = 0.06. After excluding patients with myeloma and lymphoma, IgG serum levels at diagnosis of cGvHD of 122 patients were correlated with survival. IgG levels above normal were associated with worse 2-year overall survival (OS), p = 0.04, compared to normal or low IgG levels. Platelet count at diagnosis remains the most valid prognostic factor for survival of patients with cGvHD even in the era of NIH grading. High IgG level at diagnosis of cGVHD represents a potential negative prognostic parameter that deserves further investigation.

KW - Adolescent

KW - Adult

KW - Aged

KW - Female

KW - Graft vs Host Disease

KW - Humans

KW - Male

KW - Middle Aged

KW - National Institutes of Health (U.S.)

KW - Prognosis

KW - Retrospective Studies

KW - Survival Rate

KW - United States

KW - Young Adult

U2 - 10.1007/s00277-015-2452-6

DO - 10.1007/s00277-015-2452-6

M3 - SCORING: Journal article

C2 - 26204824

VL - 94

SP - 1727

EP - 1732

JO - ANN HEMATOL

JF - ANN HEMATOL

SN - 0939-5555

IS - 10

ER -